NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused ...

The following is a summary of “Aggregate index of systemic inflammation tied to increased fatty liver disease risk: insights ...

Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biopharmaceutical company developing innovative fibrosis-focused therapies, has ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Metabolic dysfunction-associated steatotic liver disease in pregnant women is a risk factor for preterm birth.

A recommended 150 minutes per week at moderate intensity can help reduce liver inflammation and rid the organ of fat. Antioxidants and other compounds in coffee (even decaf) can help protect against ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Discover a study that suggests that dual therapy could offer a safer and more effective approach to treating MASLD.